2024-516774-30-00已完成1 期
A study to assess the safety, tolerability and pharmacokinetics of tideglusib in subjects with hepatic impairment compared to healthy subjects.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Dr Mike Snape
Scientific
Amo Pharma Limited
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A study to assess the safety, tolerability and pharmacokinetic properties of CEP-37248, a drug for the treatment of autoimmune inflammatory diseases, in healthy men.Autoimmune disease10003816NL-OMON40424TEVA Pharma93
招募中
不适用
A study to assess the safety, tolerability, and pharmacokinetics of FM101 after single and multiple ascending dose administration to healthy subjects.ASH (non-alcoholic steatohepatitis)NL-OMON27747Future Medicine Ltd.50
已完成
不适用
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male ParticipantsjRCT2071210026Astellas Pharma Inc.12
招募中
1 期
A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK4771261 in healthy participants and participants with autosomal dominant polycystic kidney disease.Kidney Disease2024-516095-15-00Glaxosmithkline Research & Development Limited21
招募中
不适用
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors.jRCT2031230712Amgen K.K.220